AN2 Therapeutics, Inc.
ANTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001880438
In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $11.6K in total
- 1
- Insider sellsLast 90 days, $343.0K in total
- 5
- 13F holdersQ2 2026, +14 vs. previous quarter
- 66
- 13F valueReported value at the end of Q2 2026
- $119.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ANTX, Q2 2026
No superinvestor reported holding ANTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by AN2 Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 (view filing)7:45 PM ET | Sep 9 | 2 days | Readnour Robin ShaneDirector | SSale | −1.11K | $6.02 | −$6.67K | −0.2%624.8K after | 2 lots10b5-1 |
| Sep 8, 2026 (view filing)7:42 PM ET | Sep 3-8 | 5 days | Readnour Robin ShaneDirector | SSale | −16.1K | $6.04 | −$97.3K | −2.5%625.4K after | 4 lots10b5-1 |
| Sep 4, 2026 (view filing)4:25 PM ET | Sep 1 | 3 daysLate | Williams Sarah JoannePrincipal Accounting Officer | SSale | −272 | $5.53 | −$1.50K | −0.4%66.3K after | |
| Sep 2, 2026 (view filing)6:43 PM ET | Sep 1 | 1 day | FitzPatrick Margaret MDirector | PPurchase | +2.10K | $5.53 | +$11.6K | +24.4%10.7K after | |
| Aug 19, 2026 (view filing)5:58 PM ET | Aug 17 | 2 days | Readnour Robin ShaneDirector | SSale | −35.4K | $6.01 | −$212.7K | −5.3%633.9K after | 2 lots10b5-1 |
| Jul 10, 2026 (view filing)6:15 PM ET | Jul 8 | 2 days | Eizen Joshua MSee Remarks | SSale | −5.95K | $4.17 | −$24.8K | −2.8%206.6K after | |
| Jun 2, 2026 (view filing) | May 29 | 4 days | Williams Sarah JoannePrincipal Accounting Officer | SSale | −265 | $4.43 | −$1.17K | −0.4%66.6K after | |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Williams Sarah JoannePrincipal Accounting Officer | SSale | −327 | $1.06 | −$346.62 | −0.5%66.8K after | |
| Jan 7, 2026 (view filing) | Jan 5-6 | 2 days | Day LucyChief Financial Officer | SSale | −8.81K | $1.01 | −$8.86K | −10.5%75.4K after | 2 lots |
| Jan 7, 2026 (view filing) | Jan 5-6 | 2 days | Prior Stephen DavidChief Strategy Officer | SSale | −6.46K | $1.00 | −$6.49K | −9.9%59.1K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in AN2 Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 3,153,640 | $15.3M | 1.39% | 00.0% | Unchanged |
| Commodore Capital LP | 2,933,680 | $14.2M | 0.85% | +599,967+25.7% | Added |
| Millennium Management LLC | 2,318,692 | $11.2M | 0.01% | +96,190+4.3% | Added |
| BlackRock, Inc. | 1,665,494 | $8.06M | 0.00% | +1,346,726+422.5% | Added |
| Spruce Street Capital LP | 1,661,073 | $8.04M | 1.58% | 00.0% | Unchanged |
| Almitas Capital LLC | 1,469,129 | $7.11M | 1.70% | −10,000−0.7% | Reduced |
| Vanguard Capital Management LLC | 1,238,705 | $6.00M | 0.00% | +227,627+22.5% | Added |
| Adage Capital Partners GP, L.L.C. | 1,000,000 | $4.84M | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 951,997 | $4.61M | 0.00% | +796,758+513.2% | Added |
| Boxer Capital Management, LLC | 749,035 | $3.63M | 0.27% | 00.0% | Unchanged |